Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website.
The company’s participation in this prestigious conference underscores its commitment to advancing mental health treatments. Helus Pharma is focused on developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. These investigational therapies aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
The fireside chat provides an opportunity for investors and industry observers to gain insights into Helus Pharma’s clinical programs, regulatory strategy, and vision for transforming the mental health treatment landscape. With class-leading data, the company aims to provide durable improvements in mental health through its novel approach.
The full press release is available at https://ibn.fm/1QdP7. For the latest news and updates relating to HELP, visit the company’s newsroom at https://ibn.fm/HELP.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. The company invites stakeholders to learn more by visiting www.helus.com or following the team on social media platforms.
